Prophase Labs Stock Buy Hold or Sell Recommendation
| PRPH Stock | USD 0.42 0.03 6.04% |
Given the investment horizon of 90 days and your typical level of risk aversion, our recommendation regarding ProPhase Labs is 'Strong Sell'. The recommendation algorithm takes into account all of ProPhase Labs' available fundamental, technical, and predictive indicators you will find on this site.
Check out ProPhase Labs Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide. In addition, we conduct extensive research on individual companies such as ProPhase and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
ProPhase |
Execute ProPhase Labs Buy or Sell Advice
The ProPhase recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on ProPhase Labs. Macroaxis does not own or have any residual interests in ProPhase Labs or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute ProPhase Labs' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
ProPhase Labs Trading Alerts and Improvement Suggestions
| ProPhase Labs generated a negative expected return over the last 90 days | |
| ProPhase Labs has high historical volatility and very poor performance | |
| ProPhase Labs has some characteristics of a very speculative penny stock | |
| The company reported the previous year's revenue of 44.38 M. Net Loss for the year was (16.78 M) with loss before overhead, payroll, taxes, and interest of (1.64 M). | |
| ProPhase Labs currently holds about 27.5 M in cash with (11.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 14.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: ProPhase Labs stock hits 52-week low at 0.41 amid sharp decline - MSN |
ProPhase Labs Returns Distribution Density
The distribution of ProPhase Labs' historical returns is an attempt to chart the uncertainty of ProPhase Labs' future price movements. The chart of the probability distribution of ProPhase Labs daily returns describes the distribution of returns around its average expected value. We use ProPhase Labs price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of ProPhase Labs returns is essential to provide solid investment advice for ProPhase Labs.
| Mean Return | -1.99 | Value At Risk | -16.67 | Potential Upside | 10.17 | Standard Deviation | 8.68 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of ProPhase Labs historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
ProPhase Stock Institutional Investors
| Shares | Bank Of America Corp | 2024-09-30 | 36.7 K | Bridgeway Capital Management, Llc | 2024-09-30 | 23.1 K | T. Rowe Price Associates, Inc. | 2024-09-30 | 17.3 K | Commonwealth Equity Services Inc | 2024-09-30 | 13.4 K | Two Sigma Securities, Llc | 2024-09-30 | 12 K | Barclays Plc | 2024-09-30 | 11.8 K | Ubs Group Ag | 2024-09-30 | 10.5 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 4.4 K | Jamison Private Wealth Management Inc | 2024-09-30 | 3 K | Vanguard Group Inc | 2024-09-30 | 655.9 K | Renaissance Technologies Corp | 2024-09-30 | 215.1 K |
ProPhase Labs Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 6.4M | 1.8M | 451K | (7.0M) | (6.3M) | (6.0M) | |
| Free Cash Flow | (4.3M) | (17.9M) | 24.6M | (14.5M) | (13.1M) | (12.4M) | |
| Other Non Cash Items | 118K | (311K) | 5.5M | 896K | 806.4K | 846.7K | |
| Capital Expenditures | 1.7M | 4.2M | 3.9M | 3.2M | 3.6M | 3.8M | |
| Net Income | (2.1M) | 6.3M | 18.5M | (16.8M) | (19.3M) | (18.3M) | |
| End Period Cash Flow | 6.8M | 8.7M | 9.1M | 2.1M | 1.9M | 1.8M | |
| Change To Inventory | (1.5M) | (1.7M) | 702K | 135K | 155.3K | 163.0K | |
| Depreciation | 458K | 3.6M | 5.1M | 6.7M | 7.7M | 8.1M | |
| Dividends Paid | 2.9M | 4.5M | 9.4M | 193K | 222.0K | 210.9K | |
| Change To Netincome | 796K | (318K) | 11.2M | 9.4M | 10.8M | 11.3M | |
| Investments | (720K) | (19.7M) | (2.1M) | (5.1M) | (5.9M) | (6.2M) |
ProPhase Labs Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to ProPhase Labs or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that ProPhase Labs' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a ProPhase stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.81 | |
β | Beta against Dow Jones | -2.49 | |
σ | Overall volatility | 9.09 | |
Ir | Information ratio | -0.24 |
ProPhase Labs Volatility Alert
ProPhase Labs is displaying above-average volatility over the selected time horizon. ProPhase Labs is a potential penny stock. Although ProPhase Labs may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in ProPhase Labs. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on ProPhase instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.ProPhase Labs Fundamentals Vs Peers
Comparing ProPhase Labs' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze ProPhase Labs' direct or indirect competition across all of the common fundamentals between ProPhase Labs and the related equities. This way, we can detect undervalued stocks with similar characteristics as ProPhase Labs or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of ProPhase Labs' fundamental indicators could also be used in its relative valuation, which is a method of valuing ProPhase Labs by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare ProPhase Labs to competition |
| Fundamentals | ProPhase Labs | Peer Average |
| Return On Equity | -0.51 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Profit Margin | (1.46) % | (1.27) % |
| Operating Margin | (3.16) % | (5.51) % |
| Current Valuation | 40.07 M | 16.62 B |
| Shares Outstanding | 23.87 M | 571.82 M |
| Shares Owned By Insiders | 14.33 % | 10.09 % |
| Shares Owned By Institutions | 7.63 % | 39.21 % |
| Number Of Shares Shorted | 116.38 K | 4.71 M |
| Price To Earning | 6.59 X | 28.72 X |
| Price To Book | 0.29 X | 9.51 X |
| Price To Sales | 0.60 X | 11.42 X |
| Revenue | 44.38 M | 9.43 B |
| Gross Profit | (1.64 M) | 27.38 B |
| EBITDA | (14.83 M) | 3.9 B |
| Net Income | (16.78 M) | 570.98 M |
| Cash And Equivalents | 27.5 M | 2.7 B |
| Cash Per Share | 1.72 X | 5.01 X |
| Total Debt | 21.38 M | 5.32 B |
| Debt To Equity | 0.19 % | 48.70 % |
| Current Ratio | 4.20 X | 2.16 X |
| Book Value Per Share | 2.74 X | 1.93 K |
| Cash Flow From Operations | (11.35 M) | 971.22 M |
| Short Ratio | 7.04 X | 4.00 X |
| Earnings Per Share | (1.53) X | 3.12 X |
| Target Price | 21.0 | |
| Number Of Employees | 113 | 18.84 K |
| Beta | -0.095 | -0.15 |
| Market Capitalization | 10.7 M | 19.03 B |
| Total Asset | 91.93 M | 29.47 B |
| Retained Earnings | (5.03 M) | 9.33 B |
| Working Capital | 26.73 M | 1.48 B |
| Current Asset | 9.73 M | 9.34 B |
Note: Acquisition by Hirsch Warren of 40000 shares of ProPhase Labs at 7.31 subject to Rule 16b-3 [view details]
ProPhase Labs Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as ProPhase . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 0.42 | |||
| Day Typical Price | 0.42 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.03) |
About ProPhase Labs Buy or Sell Advice
When is the right time to buy or sell ProPhase Labs? Buying financial instruments such as ProPhase Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having ProPhase Labs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Management Thematic Idea Now
Health Management
Major hospitals and healthcare providers. The Health Management theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Management Theme or any other thematic opportunities.
| View All Next | Launch |
Check out ProPhase Labs Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.81) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.